Purpose Individual variability in the endogenous CYP3A metabolite 4β-hydroxycholesterol (4βOHC) is substantial, but to which extent this is determined by genetic and nongenetic factors remains unclear. The aim of the study was to evaluate the explanatory power of candidate genetic variants and key nongenetic factors on individual variability in 4βOHC levels in a large naturalistic patient population. Methods We measured 4βOHC concentration in serum samples from 655 patients and used multiple linear regression analysis to estimate the quantitative effects of CYP3A4*22, CYP3A5*3, and POR*28 variant alleles, comedication with CYP3A inducers, inhibitors and substrates, sex, and age on individual 4βOHC levels. Results 4βOHC concentration ranged >100-fold in the population, and the multiple linear regression model explained about one fourth of the variability (R 2 = 0.23). Only comedication with inducers or inhibitors, sex, and POR genotype were significantly associated with individual variability in 4βOHC level. The estimated quantitative effects on 4βOHC levels were greatest for inducer comedication (+>313%, P < 0.001), inhibitor comedication (−34%, P = 0.021), and female sex (+30%, P < 0.001), while only a modestly elevated 4βOHC level was observed in carriers vs. noncarriers of POR*28 (+11%, P = 0.023). Conclusions These findings suggest that the CYP3A4*22, CYP3A5*3, and POR*28 variant alleles are of limited importance for overall individual variability in 4βOHC levels compared to nongenetic factors.
Introduction
Cytochrome P450 3A (CYP3A) enzymes are involved in the metabolism of 30-50% of clinically used drugs [1] . Within the human CYP3A subfamily, CYP3A4 and CYP3A5 are the most relevant enzymes in drug metabolism [1] . CYP3A4 and CYP3A5 display >85% amino acid sequence homology and share similar substrate specificity, although various substrates might exhibit different enzyme preferences [2] . CYP3A4 and CYP3A5 enzymes are highly expressed in liver and intestine with a >100-fold interindividual variability [1] . Variability in CYP3A5 activity is largely explained by genetics. The most studied gene variant is the CYP3A5*3 (rs776746) allele, which alters mRNA splicing and introduces a premature stop codon [1] . Approximately 80-90% of Europeans are homozygous CYP3A5*3 carriers and consequently lack the functional CYP3A5 enzyme [3, 4] . In contrast, predictive genetic factors for the CYP3A4 phenotype are scarce. To date, the genetic factor with strongest reported impact on the CYP3A4 phenotype is the CYP3A4*22 (rs35599367) allele, which has been linked to reduced CYP3A4 enzyme activity in human livers [5] . The Electronic supplementary material The online version of this article (doi:10.1007/s00228-016-2178-y) contains supplementary material, which is available to authorized users. CYP3A4*22 allele frequency is reported to be 4-9% among Europeans [4] .
The CYP3A phenotype may also be influenced by genetic factors outside the CYP3A4 and CYP3A5 loci, e.g., cytochrome P450 oxidoreductase (POR), which is responsible for electron transfer to microsomal CYP enzymes. The common POR*28 (rs1057868) allele is characterized by an amino acid substitution (NP_000932.3:p.Ala503Val) in the electronbinding domain, and the allele frequency ranges from 26 to 31% in European populations [4] . The POR*28 allele has been associated with both increased and decreased drug metabolism, depending on the CYP enzyme and substrate investigated [6] [7] [8] [9] .
In addition to genetic factors, a number of nongenetic factors influence CYP3A metabolism. Use of enzyme inducers or inhibitors is regarded as an important nongenetic source to altered CYP3A metabolism. Moreover, infection and inflammation have been linked to reduced CYP3A phenotype, possibly due to proinflammatory cytokines leading to downregulation of CYP3A [10] . Sex may also cause altered CYP3A activity with reported higher metabolic rates in females compared to males [1] . Age is another nongenetic factor of potential importance for drug metabolism, but the reported effect of age on CYP3A metabolism is inconsistent [11] .
Midazolam is considered the gold standard among CYP3A4 probe drugs for measuring the CYP3A4 phenotype. Recently, efforts have been made to identify endogenous biomarkers that reflect the extensive interindividual variability in the CYP3A phenotype as noninvasive alternatives to the use of probe drug administration. Among endogenous CYP3A biomarkers, 4β-hydroxycholesterol (4βOHC) appears as the most promising candidate. 4βOHC was first reported to be formed from cholesterol solely by CYP3A4 [12] . However, more recent studies have reported an association between the CYP3A5 genotype and 4βOHC levels, suggesting involvement also of the CYP3A5 enzyme [13] [14] [15] [16] . Thus, 4βOHC is often regarded as a composite CYP3A biomarker.
The use of 4βOHC as a biomarker for CYP3A induction is well established [17] , and several studies have also shown an impact of inhibition [18] [19] [20] . Furthermore, significant correlations between oral and intravenous midazolam clearance and 4βOHC concentrations in healthy volunteers have been reported [21] , and 4βOHC levels may reflect both intestinal and hepatic CYP3A phenotype [22] . In addition to the practical advantages with an endogenous biomarker, 4βOHC levels are not affected by P-glycoprotein and display limited intraindividual variability under stable conditions [23, 24] . Altogether, this supports the usefulness of 4βOHC as an endogenous CYP3A metric, but further studies are needed to validate 4βOHC as a biomarker of CYP3A activity.
To date, there is only limited knowledge of the relative and combined impact of multiple genetic and nongenetic factors on CYP3A-mediated metabolism measured as 4βOHC concentration. The aim of the present study was to evaluate the explanatory power of candidate genetic variants (CYP3A4*22, CYP3A5*3, and POR*28) and key nongenetic factors (age, sex, and comedication with CYP3A inducers, inhibitors, or substrates) on interindividual variability in 4βOHC levels in a large naturalistic patient population.
Methods Patients
Serum samples from 655 patients were retrospectively collected from a routine therapeutic drug monitoring (TDM) service at the Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway, between January and July 2014. The criterion for inclusion was availability of both biobanked blood samples for genetic analyses and serum samples for 4βOHC analyses. Serum and blood samples were stored at −20°C until reanalysis. The TDM requisition forms originating from each of the included serum samples were available for review of medications in use based on information provided by the respective physicians. All requisition forms were checked for comedication with CYP3A inducers, inhibitors, or/and substrates according to the Flockhart Cytochrome P450 Drug Interaction Table [25] . Furthermore, samples with 4βOHC concentrations >60 ng/mL were screened for antiepileptic drugs to detect CYP3A inducers such as carbamazepine, phenobarbital, or phenytoin, as previous studies have shown a 4βOHC concentration range from 61 to 783 ng/mL in Scandinavian patients treated with enzyme-inducing antiepileptics [12, 22] . The study was approved by the Norwegian Regional Committee for Medical and Health Research Ethics South-East.
Determination of genotypes
DNA was extracted from EDTA blood samples using the MagNA Pure 96 instrument (Roche Applied Science, P e n z b e rg , G e r m a n y ) . A n a l y s e s o f C Y P 3 A 4 * 2 2 (NM_001202855.2:c.522-191C>T; rs35599367), CYP3A5*3 (NM_000777.3:c.219-237A>G; rs776746), and POR*28 (NM_000941.2:c.1508C>T; rs1057868) alleles were performed by real-time polymerase chain reaction and melt curve analysis with hybridization probes on the LightCycler® 480 instrument (Roche). The detailed analysis conditions and sequences of primers and hybridization probes are available upon request. Absence of variant alleles was interpreted as presence of the wild-type allele (*1).
Measurement of 4β-hydroxycholesterol
The 4βOHC concentration was determined in serum by a previously published ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method using atmospheric pressure chemical ionization [22] . An additional filtration step was added after liquid-liquid extraction to remove lipid precipitations. The retention time of 4βOHC was approximately 3 min, while the retention time of 4αOHC was 2.5 min. The lower limit of quantification (LLOQ) was 10 ng/mL. Intraday and interday precision for the method was <8% at a concentration level of 10 ng/mL and <4% at a concentration of 644 ng/mL (n = 6), while the corresponding intraday and interday accuracies were <15 and <2%, respectively (n = 6).
Statistical analysis
Statistical analyses were performed using the Predictive Analysis Software (PASW) Statistics version 21 (SPSS, Chicago, IL). Genotype frequencies were tested for deviations from the Hardy-Weinberg equilibrium using the chi-squared test. The effects of candidate genotypes, age, sex, and comedication with identified CYP3A inducers, inhibitors, or substrates on 4βOHC concentrations were assessed using multiple linear regression analysis. The final model was built by backward elimination of covariates that were not statistically significant (P > 0.05). However, CYP3A5 and CYP3A4 genotypes were included in the final model regardless of the significance level. The adjusted value of R 2 from the linear model was regarded as a measure of the explained variability. P < 0.05 was considered statistically significant. GraphPad Prism version 6 was used for graphical presentations (GraphPad Software Inc., San Diego, CA).
Results

Patient characteristics
The majority of 655 patients included were Caucasians, and 367 (56.0%) were females. Median age was 43 years (range 6 to 98 years). The majority of the patients had measured drugs used for psychiatric disorders (e.g., antidepressants, antipsychotics, and antiepileptic mood stabilizers). Supplementary Table 1 provides a detailed overview of centrally acting drugs used by the patients according to information on the requisition forms and analyses of serum samples. In total, treatment with CYP3A substrates was registered in 159 patients (24.3%). Twenty-nine patients had 4βOHC concentration >60 ng/mL, and CYP3A-inducing antiepileptic drugs were detected in samples from six of these patients (n = 5 with carbamazepine, n = 1 with phenobarbital), while five samples did not contain enough serum for the analysis of antiepileptic drugs (range 4βOHC 62 to 116 ng/mL). Weak or moderate CYP3A-inhibiting antidepressants were present in samples from 18 subjects (n = 16 with fluoxetine, n = 2 with fluvoxamine). Additionally, one patient's requisition form specified use of diltiazem, a moderate CYP3A inhibitor. Samples from 23 patients (3.5%) presented 4βOHC levels <LLOQ. Nevertheless, the measured concentrations were included in the final regression model, as no significant changes to the model were observed when these values were set to LLOQ. Distributions of the different CYP3A4, CYP3A5, and POR genotypes are presented in Table 1 . All genotype frequencies were in accordance with the Hardy-Weinberg equilibrium.
Effects of genetic and nongenetic factors on 4βOHC concentrations
The median 4βOHC concentration in the whole population was 24.8 ng/mL with a 120-fold variability between patients (range 4.6 to 549 ng/mL). Before statistical analysis, the 4βOHC concentrations were tested for normality, which revealed significant right-hand tailing. This was handled by truncating all 4βOHC measurements >100 ng/mL, which were set to 100 ng/mL (n = 8). Among measurements >100 ng/mL, six originated from subjects comedicated with CYP3A inducers (median = 227 ng/mL, range 101 to 549 ng/ mL) (Fig. 1) .
Multiple linear regression analysis was performed to estimate effects of candidate genotypes, based on the presence of CYP3A4*22, CYP3A5*3, and POR*28 variant alleles, and nongenetic factors including age, sex, and comedication with CYP3A inducers, inhibitors, and substrates on 4βOHC concentrations. In the multivariate analysis, only comedication CI confidence interval with CYP3A inducers or inhibitors, sex, and presence of the POR*28 variant allele were identified as independent variables significantly associated with 4βOHC concentration ( Table 2) . The final regression model explained 22.8% (adjusted R 2 = 0.228) of the total interindividual variability in 4βOHC concentrations.
Comedication with a CYP3A inducer was the strongest predictor of 4βOHC concentrations with a more than 313% elevation in 4βOHC levels compared to patients without exposure to CYP3A4 inducers (P < 0.001). In comparison, comedication with a CYP3A inhibitor was associated with a 33.8% lower 4βOHC concentration than that of patients without exposure to CYP3A inhibitors (P = 0.021), while female sex was associated with a 30.3% higher 4βOHC concentration than that of male patients (P < 0.001). As the only significant genotype in the analysis, presence of the POR*28 allele was associated with an 11.4% higher 4βOHC concentration compared with that of patients with POR*1/*1 (P = 0.023) ( Table 2 ). There were no significant differences in 4βOHC levels between CYP3A5 and CYP3A4 genotype groups; however, 4βOHC concentrations were numerically higher and lower among carriers vs. noncarriers of the CYP3A5*1 (+9.2%) and CYP3A4*22 (−12.3%) alleles, respectively (P > 0.1). Moreover, comedication with CYP3A substrates was not a significant covariate in the model (P > 0.3), and age was neither significant as a continuous covariate (P > 0.9), nor when the population was split into age subgroups of <65 and ≥65 years (P > 0.2). No significant interactions between covariates were discovered. Similar findings were observed in a separate regression model, which only included the data from the adult population (≥18 years, n = 625) (results not shown). No significant association was detected between fluoxetine doses and 4βOHC concentrations in the 16 patients comedicated with fluoxetine (P = 0.3, simple linear regression analysis), which was the only CYP3A-interacting drug where dose information was available for a sufficient number of patients to perform statistical analysis.
Discussion
This study showed a >100-fold difference in 4βOHC concentrations among the 655 included subjects, supporting an extensive interindividual variability in in vivo CYP3A activity. About one fourth of the variability was explained by the factors included in the multiple linear regression model, and nongenetic variables were found to be of greater importance for 4βOHC concentration than the included genotypes. Overall, comedication with CYP3A inducers or inhibitors had the strongest impact on 4βOHC concentration, which supports drug interactions as a crucial source behind differences in pharmacokinetics and possibly clinical outcome of CYP3A substrate drugs.
Comedication with a CYP3A inducer was estimated to have the greatest quantitative effect on 4βOHC concentration in the study population. The multiple linear regression model predicted a >4-fold higher 4βOHC concentration when using a CYP3A inducer. Since 4βOHC values in all six subjects using a CYP3A inducer were truncated to achieve a Gaussian distribution, it is important to be aware that the multivariate analysis underestimated the quantitative impact of an inducer on 4βOHC concentration. Previous studies have reported a ≥10-fold higher 4βOHC level during use of antiepileptic CYP3A inducers [12, 22] , which is in line with the visual comparison of median 4βOHC values in induced vs. noninduced subjects in the present study population. Nevertheless, our findings confirm that 4βOHC is a sensitive biomarker in detecting CYP3A induction, as reported in several earlier studies [12, 22, [26] [27] [28] [29] . The +/− signs express the estimated increase/decrease in 4βOHC concentration associated with a tested variable Fig. 1 Scatter plot of individual 4β-hydroxycholesterol (4βOHC) concentrations for subjects with (n = 6) and without (n = 649) CYP3A-inducing comedication. Eight subjects had 4βOHC concentration >100 ng/mL (dotted line)
While 4βOHC is well established as a biomarker for detecting CYP3A induction, it has been debated whether it is a suitable marker for assessing CYP3A inhibition [19, 21, 26, 29] . The present study found that comedication with a CYP3A inhibitor was the second strongest predictor of 4βOHC concentration, causing an estimated 34% reduction of 4βOHC levels. The three comedicated drugs defined as inhibitors in the study are reported to display weak to moderate CYP3A inhibitory effects [30] [31] [32] . The fact that use of weak to moderate CYP3A inhibitors was associated with a significant reduction in 4βOHC levels supports that 4βOHC captures inhibition of CYP3A in vivo. An advantage of the present TDM material was that treatment with inhibiting drugs probably had been ongoing for longer periods prior to sampling, implying that steady-state conditions had been achieved for both the inhibitors and 4βOHC levels. As 4βOHC has a long elimination half-life, i.e., about 17 days [24] , variable and limited treatment duration with CYP3A inhibitors before sampling might have caused conflicting findings in previous studies investigating effects of CYP3A inhibitors on 4βOHC levels [21, 26, 29] .
Despite that in vitro data indicate only a minor role of CYP3A5 compared to CYP3A4 in the formation of 4βOHC [33] , several studies have found significantly higher 4βOHC levels in CYP3A5 expressors vs. nonexpressors [13] [14] [15] [16] . However, these studies have been based on a limited number of subjects of rather homogenous populations [14] [15] [16] , and only one of the studies was performed among Europeans [13] . In our large patient material, no significant effect of the CYP3A5 genotype on 4βOHC levels was observed. This is in accordance with in vitro data showing that CYP3A4 is 20-fold more effective than CYP3A5 in catalyzing the formation of 4βOHC [33] , as well as smaller studies in healthy volunteers and renal transplant recipients showing no effect of the CYP3A5 genotype on baseline 4βOHC [23] or 4βOHC/cholesterol ratio [34, 35] . The fact that observed 4βOHC levels were similar in heterozygous (n = 113) and homozygous (n = 11) carriers of CYP3A5*1 in our study further indicates a limited role of CYP3A5 in the in vivo formation of this biomarker. It is therefore possible that 4βOHC is more of a CYP3A4 activity marker than a composite CYP3A activity marker, but additional studies are needed to determine the role of CYP3A5 in the formation of 4βOHC.
Only a few previous studies have explored the impact of POR and CYP3A4 genotypes on 4βOHC levels. Woolsey et al. did not find any association between CYP3A4*22, CYP3A5*3, or POR*28 alleles and the 4βOHC/cholesterol ratio in 51 healthy subjects [34] , while Vanhove et al. found a decreased 4βOHC/cholesterol ratio in CYP3A4*22 carriers and an increased 4βOHC/cholesterol ratio among CYP3A4*1b carriers in a study of 147 stable renal transplant recipients (P < 0.01) [35] . In our larger material of 655 subjects, POR*28 was the only included genetic variant with significant impact on 4βOHC concentration. Carriers of the POR*28 variant allele were estimated to have 11% higher 4βOHC levels than noncarriers, indicating that the POR*28 allele contributes to a slightly increased CYP3A(4) catalytic activity. However, previous in vitro studies have reported conflicting effects of POR*28 on metabolism of different CYP3A substrates, e.g., no change in metabolism for quinidine and erythromycin but reduced metabolism for testosterone and midazolam [7] . In vivo studies have reported that POR*28 enhances midazolam metabolism [6] , while conflicting findings are reported for tacrolimus [8, 36, 37] . Thus, it appears that the effect of POR*28 on CYP3A(4) metabolism is substrate dependent and of little generic relevance. Regarding CYP3A4*22, this variant allele has been highlighted as a candidate for routine genotyping, primarily during treatment initiations of tacrolimus, where it has been associated with a 30-40% reduced dose requirement to achieve target concentrations [38] [39] [40] . However, in our study, no significant impact of CYP3A4*22 on 4βOHC levels was observed. As the previously observed effect of CYP3A4*22 on drug metabolism has been limited, combined with the relatively rare occurrence of CYP3A4*22, this variant allele appears to be of limited general importance for the overall variability in the CYP3A(4) phenotype.
We found a 30% higher 4βOHC level in females than in males. This is in line with previous studies that have shown both higher CYP3A4 expression and activity in females than in males [13, 14, 41, 42] . The mechanism behind sex differences in the CYP3A4 phenotype is not elucidated, but may involve hormonal differences [43] . Higher clearance of several CYP3A4 substrate drugs has been reported among females compared to males, but whether this is of clinical importance remains unclear [44] .
In this study, we used 4βOHC serum concentration as a measure of CYP3A activity without adjusting for individual cholesterol levels. Diczfalusy et al. reported that variation in cholesterol concentration only explained about 9% of 4βOHC variation [13] . Furthermore, only marginal differences in correlations were reported between unadjusted 4βOHC and the 4βOHC/cholesterol ratio with midazolam clearance [21] . Thus, measuring 4βOHC without adjusting for cholesterol will generally be sufficient for determining the interindividual CYP3A phenotype. However, the retrospective and naturalistic design of the present study implies some methodological limitations. For example, information about comedication with CYP3A inducers and inhibitors was obtained from TDM requisition forms. This procedure implies uncertainty regarding actual use of medication, including potential use of herbal drugs, e.g., St. John's Wort, which may affect the CYP3A phenotype. As an attempt to improve the identification of comedication with antiepileptic CYP3A inducers, samples with measured 4βOHC concentration >60 ng/mL were reanalyzed to reveal the potential presence of carbamazepine, phenobarbital, or phenytoin in samples with high 4βOHC levels. These enzyme-inducing antiepileptics are probably among the most commonly used CYP3A inducers. Actually, six out of eight samples in the study with 4βOHC concentration >100 ng/mL were confirmed to contain carbamazepine or phenobarbital, and two of these cases were identified by UPLC-MS/MS analysis without information of use on TDM requisition forms. Although the total number of patients using CYP3A inducers in the study was limited (n = 6), the 4βOHC concentrations in these patients (101-549 ng/mL) are perfectly in line with a previous, larger study among Norwegian patients using enzyme-inducing antiepileptics [22] . There are several factors of potential importance for the CYP3A phenotype that were not assessed in the present study due to lack of information availability. These include patient/clinical characteristics like somatic conditions, inflammatory state, organ function relevant for CYP3A metabolism or subsequent 4βOHC elimination, and body weight. However, despite these study limitations, the final multiple linear regression model explained almost a fourth of the variation in 4βOHC concentration, which is a substantial explanatory power considering the study's naturalistic design.
In conclusion, this study shows that nongenetic factors are of greater importance than the CYP3A4*22, CYP3A5*3, and POR*28 variant alleles for individual variability in 4βOHC levels among European patients. Comedication with enzyme inducers or inhibitors and sex are likely primary determinants of the CYP3A(4) phenotype and together explain a major part of the overall individual variability in 4βOHC serum concentrations.
